Difference between revisions of "Team:SMMU-China/Human Practices detail 1"

(Created page with "{{SMMU-China}} <html> <link rel="stylesheet" href="https://2019.igem.org/wiki/index.php?title=Template:SMMU-China/CSS_main&action=raw&ctype=text/css" /> <!--<link rel="styles...")
 
Line 126: Line 126:
  
 
<div class="medium_framework">
 
<div class="medium_framework">
<p><b>“Engineered NK cells with synthetic Notch Receptors” & “How to ensure biosafety and biocompatibility”</b></p>
 
 
<p>Professor Lu agrees with our idea in early diagnosis and prevention of cancer. However, she said, heterogeneity of carcinoma is the most foremost obstacles you have to conquer. To deal with this problem, she suggested us to design different receptors to recognize different already known antigens expressed by breast cancer. Since you have synthetic Notch receptor, you can equip your system as many receptors as possible, and this could effectively handle the heterogeneity of cancers, even if our understanding about breast cancer is growing, your system could also be improved.</p>
 
<p>Professor Lu agrees with our idea in early diagnosis and prevention of cancer. However, she said, heterogeneity of carcinoma is the most foremost obstacles you have to conquer. To deal with this problem, she suggested us to design different receptors to recognize different already known antigens expressed by breast cancer. Since you have synthetic Notch receptor, you can equip your system as many receptors as possible, and this could effectively handle the heterogeneity of cancers, even if our understanding about breast cancer is growing, your system could also be improved.</p>
 
<p>Also based on this artificial tumor surveillance and killing system, Lu pointed out two problems which must be proved in the project. First, the safety and ethical issues of this new tumor treatment. Second, in our system, how reaction/screening part correspond to the signal from the detection part efficiently? Actually, from basic research to clinical treatment, there is a very long way to go. Considering about the safety and ethical issues, we will do more basic researches and follow the process of clinical research legally. And we have done some experiments to figure out if the reaction/screening part can react to the signal from the detection part efficiently. And you can <u><a href="https://2019.igem.org/Team:SMMU-China/Design">click here</a></u> to see more.</p>
 
<p>Also based on this artificial tumor surveillance and killing system, Lu pointed out two problems which must be proved in the project. First, the safety and ethical issues of this new tumor treatment. Second, in our system, how reaction/screening part correspond to the signal from the detection part efficiently? Actually, from basic research to clinical treatment, there is a very long way to go. Considering about the safety and ethical issues, we will do more basic researches and follow the process of clinical research legally. And we have done some experiments to figure out if the reaction/screening part can react to the signal from the detection part efficiently. And you can <u><a href="https://2019.igem.org/Team:SMMU-China/Design">click here</a></u> to see more.</p>

Revision as of 12:44, 19 October 2019

page_banner_default
Human Practices
Interview with Professor Lu Jian

Professor Lu agrees with our idea in early diagnosis and prevention of cancer. However, she said, heterogeneity of carcinoma is the most foremost obstacles you have to conquer. To deal with this problem, she suggested us to design different receptors to recognize different already known antigens expressed by breast cancer. Since you have synthetic Notch receptor, you can equip your system as many receptors as possible, and this could effectively handle the heterogeneity of cancers, even if our understanding about breast cancer is growing, your system could also be improved.

Also based on this artificial tumor surveillance and killing system, Lu pointed out two problems which must be proved in the project. First, the safety and ethical issues of this new tumor treatment. Second, in our system, how reaction/screening part correspond to the signal from the detection part efficiently? Actually, from basic research to clinical treatment, there is a very long way to go. Considering about the safety and ethical issues, we will do more basic researches and follow the process of clinical research legally. And we have done some experiments to figure out if the reaction/screening part can react to the signal from the detection part efficiently. And you can click here to see more.